A Real World Report on Intravenous High-Dose and Non-High-Dose Proton-Pump Inhibitors Therapy in Patients with Endoscopically Treated High-Risk Peptic Ulcer Bleeding
Background and Study Aims. The optimal dose of intravenous proton-pump inhibitor (PPI) therapy for the prevention of peptic ulcer (PU) rebleeding remains controversial. This study aimed to understand the real world experiences in prescribing high-dose PPI and non-high-dose PPI for preventing rebleed...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2012/858612 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549859829219328 |
|---|---|
| author | Lung-Sheng Lu Sheng-Chieh Lin Chung-Mou Kuo Wei-Chen Tai Po-Lin Tseng Kuo-Chin Chang Chung-Huang Kuo Seng-Kee Chuah |
| author_facet | Lung-Sheng Lu Sheng-Chieh Lin Chung-Mou Kuo Wei-Chen Tai Po-Lin Tseng Kuo-Chin Chang Chung-Huang Kuo Seng-Kee Chuah |
| author_sort | Lung-Sheng Lu |
| collection | DOAJ |
| description | Background and Study Aims. The optimal dose of intravenous proton-pump inhibitor (PPI) therapy for the prevention of peptic ulcer (PU) rebleeding remains controversial. This study aimed to understand the real world experiences in prescribing high-dose PPI and non-high-dose PPI for preventing rebleeding after endoscopic treatment of high-risk PU. Patients and Methods. A total of 220 subjects who received high-dose and non-high-dose pantoprazole for confirmed acute PU bleeding that were successfully treated endoscopically were enrolled. They were divided into rebleeding (n=177) and non-rebleeding groups (n=43). Randomized matching of the treatment-control group was performed. Patients were randomly selected for non-high-dose and high-dose PPI groups (n=44 in each group). Results. Univariate analysis showed, significant variables related to rebleeding were female, higher creatinine levels, and higher Rockall scores (≧6). Before case-control matching, the high-dose PPI group had higher creatinine level, higher percentage of shock at presentation, and higher Rockall scores. After randomized treatment-control matching, no statistical differences were observed for rebleeding rates between the high-dose and non-high-dose groups after case-control matching. Conclusion. This study suggests that intravenous high-dose pantoprazole may not be superior to non-high-dose regimen in reducing rebleeding in high-risk peptic ulcer bleeding after successful endoscopic therapy. |
| format | Article |
| id | doaj-art-70c129d602f64109bfc7095605020d45 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-70c129d602f64109bfc7095605020d452025-02-03T06:08:26ZengWileyGastroenterology Research and Practice1687-61211687-630X2012-01-01201210.1155/2012/858612858612A Real World Report on Intravenous High-Dose and Non-High-Dose Proton-Pump Inhibitors Therapy in Patients with Endoscopically Treated High-Risk Peptic Ulcer BleedingLung-Sheng Lu0Sheng-Chieh Lin1Chung-Mou Kuo2Wei-Chen Tai3Po-Lin Tseng4Kuo-Chin Chang5Chung-Huang Kuo6Seng-Kee Chuah7Division of Hepato-Gastroenterology, Department of Internal Medicine and Kaohsiung Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, 123 Ta-Pei Road, Niaosung Hsiang, Kaohsiung City 833, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine and Kaohsiung Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, 123 Ta-Pei Road, Niaosung Hsiang, Kaohsiung City 833, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine and Kaohsiung Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, 123 Ta-Pei Road, Niaosung Hsiang, Kaohsiung City 833, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine and Kaohsiung Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, 123 Ta-Pei Road, Niaosung Hsiang, Kaohsiung City 833, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine and Kaohsiung Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, 123 Ta-Pei Road, Niaosung Hsiang, Kaohsiung City 833, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine and Kaohsiung Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, 123 Ta-Pei Road, Niaosung Hsiang, Kaohsiung City 833, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine and Kaohsiung Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, 123 Ta-Pei Road, Niaosung Hsiang, Kaohsiung City 833, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine and Kaohsiung Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, 123 Ta-Pei Road, Niaosung Hsiang, Kaohsiung City 833, TaiwanBackground and Study Aims. The optimal dose of intravenous proton-pump inhibitor (PPI) therapy for the prevention of peptic ulcer (PU) rebleeding remains controversial. This study aimed to understand the real world experiences in prescribing high-dose PPI and non-high-dose PPI for preventing rebleeding after endoscopic treatment of high-risk PU. Patients and Methods. A total of 220 subjects who received high-dose and non-high-dose pantoprazole for confirmed acute PU bleeding that were successfully treated endoscopically were enrolled. They were divided into rebleeding (n=177) and non-rebleeding groups (n=43). Randomized matching of the treatment-control group was performed. Patients were randomly selected for non-high-dose and high-dose PPI groups (n=44 in each group). Results. Univariate analysis showed, significant variables related to rebleeding were female, higher creatinine levels, and higher Rockall scores (≧6). Before case-control matching, the high-dose PPI group had higher creatinine level, higher percentage of shock at presentation, and higher Rockall scores. After randomized treatment-control matching, no statistical differences were observed for rebleeding rates between the high-dose and non-high-dose groups after case-control matching. Conclusion. This study suggests that intravenous high-dose pantoprazole may not be superior to non-high-dose regimen in reducing rebleeding in high-risk peptic ulcer bleeding after successful endoscopic therapy.http://dx.doi.org/10.1155/2012/858612 |
| spellingShingle | Lung-Sheng Lu Sheng-Chieh Lin Chung-Mou Kuo Wei-Chen Tai Po-Lin Tseng Kuo-Chin Chang Chung-Huang Kuo Seng-Kee Chuah A Real World Report on Intravenous High-Dose and Non-High-Dose Proton-Pump Inhibitors Therapy in Patients with Endoscopically Treated High-Risk Peptic Ulcer Bleeding Gastroenterology Research and Practice |
| title | A Real World Report on Intravenous High-Dose and Non-High-Dose Proton-Pump Inhibitors Therapy in Patients with Endoscopically Treated High-Risk Peptic Ulcer Bleeding |
| title_full | A Real World Report on Intravenous High-Dose and Non-High-Dose Proton-Pump Inhibitors Therapy in Patients with Endoscopically Treated High-Risk Peptic Ulcer Bleeding |
| title_fullStr | A Real World Report on Intravenous High-Dose and Non-High-Dose Proton-Pump Inhibitors Therapy in Patients with Endoscopically Treated High-Risk Peptic Ulcer Bleeding |
| title_full_unstemmed | A Real World Report on Intravenous High-Dose and Non-High-Dose Proton-Pump Inhibitors Therapy in Patients with Endoscopically Treated High-Risk Peptic Ulcer Bleeding |
| title_short | A Real World Report on Intravenous High-Dose and Non-High-Dose Proton-Pump Inhibitors Therapy in Patients with Endoscopically Treated High-Risk Peptic Ulcer Bleeding |
| title_sort | real world report on intravenous high dose and non high dose proton pump inhibitors therapy in patients with endoscopically treated high risk peptic ulcer bleeding |
| url | http://dx.doi.org/10.1155/2012/858612 |
| work_keys_str_mv | AT lungshenglu arealworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT shengchiehlin arealworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT chungmoukuo arealworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT weichentai arealworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT polintseng arealworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT kuochinchang arealworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT chunghuangkuo arealworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT sengkeechuah arealworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT lungshenglu realworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT shengchiehlin realworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT chungmoukuo realworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT weichentai realworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT polintseng realworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT kuochinchang realworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT chunghuangkuo realworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding AT sengkeechuah realworldreportonintravenoushighdoseandnonhighdoseprotonpumpinhibitorstherapyinpatientswithendoscopicallytreatedhighriskpepticulcerbleeding |